Study Describes New Way to Place CRISPR/Cas9 Into Cancer Cells

Study Describes New Way to Place CRISPR/Cas9 Into Cancer Cells
Researchers have developed a new technology that can be used to deliver the gene-editing tool CRISPR/Cas9 into prostate cancer cells without the need for viral vectors, a proof-of-concept study demonstrates. The study, "ZIF-C for targeted RNA interference and CRISPR/Cas9 based gene editing in prostate cancer," was published in Chemical Communications. Cancer cells harbor genetic changes that enable them to grow and survive unchecked. In the broadest sense, gene therapy for cancer aims to reverse or deter these changes, leading the cancer cell to stop growing and/or die. For example, in some prostate cancer cells, abnormally high levels of the protein LAM67R help the cells spread to distant regions in the body, a process called metastasis. Reducing LAM67R levels by targeting the gene that provides instructions to make this protein — RPSA — may be therapeutically beneficial. CRISPR/Cas9 is a molecular tool that can be used to precisely edit DNA in cells and has the potential to become a cancer treatment by permanently disrupting genes associated with tumor survival. In the above example, disrupting RPSA via CRISPR could effectively reduce LAM67R levels, thus lowering the risk of metastasis. However, targeting in a gene via a cell with CRISPR requires putting genetic material (DNA or RNA) into the cell itself. Generally, cells do not easily take up new genetic material from outside themselves. At present, the most common approach for getting foreign genetic material is to use viruses, which have evolved to be highly effective at getting genes into cells (essentially a viral infection). However, in a clinical context, using viruses as vectors for gene therapy can raise safety concerns. Plus, viral therapies tend to be costly to produce. In the ne
Subscribe or to access all post and page content.